Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
84

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Transplant Circulating Tumor DNA and Recurrence Risk After Liver Transplantation for Hepatocellular Carcinoma.

Clinical transplantation·2026
Same author

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
Same author

Role of HIV-1 in IL-8 response of human stellate cells to gram-positive microbial products.

Scientific reports·2026
Same author

Artificial intelligence perceptions and experiences among first and second year medical students.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same author

Comprehensive overview of management and risk assessment of breast cancer-related lymphedema: a multidisciplinary approach.

Frontiers in oncology·2026
Same author

Under-reporting of sex-specific outcomes in reverse shoulder arthroplasty: a systematic review.

Journal of shoulder and elbow arthroplasty·2026

Related Experiment Video

Updated: Jun 21, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

200

Cholangiocarcinoma, sequential chemotherapy, and prognostic tests.

Howard W Bruckner1, Robert De Jager1, Elisheva Knopf1,2

  • 1Department of Oncology, MZB Foundation for Cancer Research, New York, NY, United States.

Frontiers in Oncology
|July 9, 2024
PubMed
Summary

This study shows that specific blood tests can predict survival in cholangiocarcinoma patients. Novel drug regimens achieve over two-year survival, demonstrating the effectiveness of these prognostic markers and treatments.

Keywords:
chemotherapycholangiocarcinomageriatricslow-dosageprognosisresistancesurvival

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Related Experiment Videos

Last Updated: Jun 21, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

200
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.3K

Area of Science:

  • Oncology
  • Clinical Trials
  • Biomarkers

Background:

  • Cholangiocarcinoma (bile duct cancer) survival is often poor, necessitating improved prognostic tools and treatments.
  • Routine blood tests are being explored as prognostic indicators for cholangiocarcinoma patients.
  • New drug regimens show potential for improving median overall survival in advanced cholangiocarcinoma.

Purpose of the Study:

  • To evaluate the efficacy of novel, low-dose chemotherapy regimens in patients with advanced intrahepatic cholangiocarcinoma.
  • To assess the predictive value of routine blood tests as prognostic markers for survival in cholangiocarcinoma.
  • To investigate the relationship between specific blood test results and patient survival outcomes.

Main Methods:

  • A single-center, IRB-approved, phase II clinical trial was conducted.
  • Patients received biweekly, one-third standard dose chemotherapy (Gemcitabine, 5-Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin) with sequential drug additions upon progression.
  • Prognostic value of blood tests (neutrophil-lymphocyte ratio, absolute neutrophil count, serum albumin, lymphocyte-monocyte ratio) was analyzed using Cox regression.

Main Results:

  • Two-year survival rates were high: 72% for patients with prior therapy and 58% for treatment-naive patients.
  • Patients with favorable prognostic blood test results demonstrated significantly longer median survival times (17 months to >2 years).
  • The novel treatment regimens were well-tolerated, with no reported hospitalizations or severe toxicities like neutropenic fever or enteritis.

Conclusions:

  • Two-year survival in advanced cholangiocarcinoma is achievable and predictable with the tested regimens and prognostic blood tests.
  • Findings support the need for phase III trials to validate these sequential regimens and prognostic markers.
  • Identifying and targeting mechanisms associated with poor response through blood tests is crucial for improving cholangiocarcinoma outcomes.